The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cancer diagnostics market size reached US$ 174.22 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 252.35 Billion by 2027, exhibiting a growth rate (CAGR) of 6.15% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Cancer diagnostics represent a range of assessments and procedures executed using sophisticated technologies to identify biomarkers, proteins, tumor type, location, and signs about the stage and presence of various cancerous tumors. They encompass imaging, tumor biopsy, laboratory tests, immunohistochemistry genetic testing, and endoscopic examination as standard assessments. These diagnostics methodologies are performed based on the patient condition and severity of disorders. Apart from this, cancer diagnostics help healthcare practitioners in developing a personalized treatment plan, evaluating specific antigens in a sample tissue by using antibodies, and providing better clinical outcomes through early diagnosis and care. As a result, they are widely adopted in hospitals and laboratories to examine breast, lung, melanoma, and colorectal cancer. Currently, they are mainly available in fluorescent in situ and comparative genomic hybridization technologies.
The increasing prevalence of cancer, owing to the rising consumption of alcoholic beverages and tobacco-based products, and the growing need for preventive, diagnostic technologies for better therapeutic effects are majorly driving the market growth. In line with this, significant enhancements in the healthcare sector and the advent of advanced oncological imaging modalities and imaging technologies to detect infections with enhanced accuracy are acting as another growth-inducing factor. Additionally, extensive investments by pharmaceutical companies to engineer cancer vaccines and novel biomarkers for the identification of potential tumor is contributing to the market growth. Moreover, the favorable initiatives being undertaken by non-governmental organizations (NGOs) and healthcare practitioners to sensitize individuals regarding the availability and benefits of early cancer diagnosis, such as instant decision-making and consequent treatment, are propelling the market growth. Other factors, such as the rapid establishment of private diagnostic centers and ongoing research and development (R&D) activities to design effective product variants with reduced treatment, hospitalization, and unavoidable intervention costs, are positively augmenting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer diagnostics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, technology, application and end user.
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG (Roche Holding AG), GE HealthCare (General Electric Company), Hologic Inc., Illumina Inc., Koninklijke Philips N.V., Pfizer Inc., Qiagen N.V, Quest Diagnostics, Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Technology, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG (Roche Holding AG), GE HealthCare (General Electric Company), Hologic Inc., Illumina Inc., Koninklijke Philips N.V., Pfizer Inc., Qiagen N.V, Quest Diagnostics, Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Clinical Decision Support Systems (CDSS) Market by Component (Hardware, Software, Services), Product (Integrated CDSS, Standalone CDSS), Type (Therapeutic, Diagnostic), Delivery Mode (On Premise, Cloud Based), Model (Knowledge Based, Non-Knowledge Based), Application (Drug Allergy Alerts, Clinical Guidelines, Drug-Drug Interactions, Clinical Reminders, and Others), and Region 2023-2028
Blockchain in Healthcare Market by Network Type (Private, Public, and Others), Application (Supply Chain Management, Data Exchange and Interoperability, Claims Adjudication and Billing Management, and Others), End Use (Healthcare Providers, Healthcare Payers, Biopharmaceutical & Medical Device Companies, and Others), and Region 2023-2028
Disinfection Robots Market by Product Type (UV-Disinfection Robot, Hydrogen Peroxide Vaporization Robot (HPV), and Others), Technology (Fully Autonomous Disinfection Robots, Semi-Autonomous Disinfection Robots), End User (Hospitals and Clinics, Research Institutes, and Others), and Region 2023-2028
Remote Healthcare Market by Service (Remote Patient Monitoring, Real Time Virtual Health, Tele-ICU), Application (Diagnosis, Cardiology, Obstetrics, Senior Care, and Others), End User (Payer, Provider, Patient, Employer Groups and Government Organizations), and Region 2023-2028
Medication Management Market by Software (Computerized Physician Order Entry System, Clinical Decision Support System, Administration Software, Inventory Management System, Automated Dispensing Systems, Assurance System), Services (Medication Analytics Services, Point-Of-Care Verification Services, Adverse Drug Event (ADE) Surveillance Services), Mode of Delivery (Web-based, Cloud-based, On-premises), End User (Pharmacies, Hospitals and Others) and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at